海翔药业：NWRD08注射液完成Ⅱ期临床首例受试者入组

Core Viewpoint - Haishang Pharmaceutical (002099.SZ) announced that its investment partner, Guoxin Haishang, has participated in the clinical trial of the first on-demand therapeutic vaccine for cancer, NWRD08, developed by Nuowei Biotechnology, which has officially started in multiple hospitals including Peking Union Medical College Hospital [1] Group 1: Product Development - NWRD08 is China's first therapeutic nucleic acid drug targeting HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL) that has entered Phase II clinical trials [1] - The drug activates specific T-cell immunity to eliminate infected cells, distinguishing it from preventive HPV vaccines, as it specifically targets patients already infected with HPV and exhibiting related lesions [1] Group 2: Treatment Advantages - NWRD08 aims to activate the body's specific CD8+ T-cell immune response to accurately identify and eliminate cells infected by HPV16/18, fundamentally preventing disease progression [1] - Compared to traditional surgical removal, this therapy allows female patients to retain their complete cervix [1]